Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 5/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6658632 | 0.83 | CDK2 (0.54) | CDK2GRM4GRM5 | |
| SCHEMBL20385536 | 0.80 | MKNK1 (0.51) | MKNK1MKNK2JAK2JAK3BTK | |
| SCHEMBL6302354 | 0.79 | CDK2 (0.69) | CDK2GRM4DRD2HTR2AHRH1 | |
| SCHEMBL6657536 | 0.75 | HCAR3 (0.55) | CDK2GRM5 | |
| SCHEMBL3146801 | 0.75 | CDK2 (0.62) | CDK2GRM4GRM5 | |
| SCHEMBL16245640 | 0.74 | ALDH1A1 (0.51) | MKNK1MKNK2JAK2JAK3JAK1 | |
| SCHEMBL4749514 | 0.73 | JAK2 (0.60) | CDK2JAK2JAK3BTKKCNH2 | |
| SCHEMBL14672478 | 0.73 | JAK2 (0.60) | CDK2JAK2JAK3BTKKCNH2 | |
| SCHEMBL3134667 | 0.73 | SLC2A1 (0.42) | JAK2JAK3BTKJAK1TYK2 | |
| SCHEMBL4749516 | 0.73 | HRH1 (0.50) | CDK2GRM4DRD2HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742935-B1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7642354-B2 | Use treating nervous system disorders, as neuroprotectants, gastrointestinal disorders, cardiovascular disorders; e.g. 2-(5-phenylpyridin-2-ylamino)-6-pyridin-2-ylpyrimidine | ICAGEN, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1742935-A1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005121126-A1 | POLYCYCLIC PYRAZINES AS POTASSIUM ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | ICAGEN, INC. (US) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239800-A1 | Polycyclic pyrazines as potassium ion channel modulators | KCNJ2, KCNH2, KCNJ1 | CDK2 3168/4885GRM4 357/4885MKNK1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.